地舒单抗医保能给报销吗？

(Denosumab) is a drug that targets the RANK ligand. Compared with bisphosphonates that have been clinically used for a long time, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. On May 28, 2010, denosumab was approved for marketing by the European Commission. On June 2, 2010, it was approved by the US FDA for use in postmenopausal women with the risk of osteoporosis, under the trade name Prolia.

The therapeutic effect of denosumab is remarkable, and it was launched in my country in May 2019 and lived up to expectations. However, the prices of original drugs on the domestic market are relatively high. Therefore, for many patients, if there is no medical insurance reimbursement, it will be difficult to purchase and use it for a long time. Can denosumab be reimbursed by medical insurance?

The entry of imported drugs into medical insurance is a relatively complex and long-term process. Desosumab (denosumab) has just been launched in my country and has not yet been included in national medical insurance, so it cannot be reimbursed.

Desosumab (denosumab) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. The European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures.

It should be noted during medication that denosumab can only be injected subcutaneously, not intravenously, intramuscularly, or intradermally. Inject 120 mg subcutaneously into the upper arm, upper thigh, or abdomen every 4 weeks to give calcium and vitamin D when needed to treat or prevent hypocalcemia.

(Denosumab) cannot be reimbursed through medical insurance. Patients may wish to purchase denosumab, which is available in Turkey. The price is relatively cheap and it is a good choice for domestic patients.